Wegovy and Pancreatitis: Risks, Symptoms and When to Act

You've just had a sharp stomach pain on Wegovy, here's how to tell whether it matters

Nausea and stomach discomfort are common in the early weeks of semaglutide treatment, particularly after a dose step-up. For most people, that discomfort is mild and settles within a few days. Pancreatitis feels different, and it's worth knowing how to tell them apart.

The hallmark of acute pancreatitis is pain that is severe rather than nagging, it often starts in the upper abdomen and radiates towards the back, and it tends to persist rather than come and go with meals. Vomiting may accompany it, but unlike the nausea of a new dose, the pain doesn't fade after an hour. If you experience this pattern, stop eating, stop the injection, and contact a GP or call 111 without delay. If the pain is severe or you cannot get through quickly, go to A&E. This is not overcautious advice, untreated pancreatitis can escalate. The NHS medicines page for semaglutide lists this as one of the serious side effects requiring urgent attention, and it mirrors the guidance issued in the MHRA's January 2026 Drug Safety Update.

Ordinary Wegovy nausea, by contrast, usually peaks in the first day or two after an injection and then eases. It rarely reaches the level of severity associated with pancreatitis, and it typically doesn't radiate to the back. That pattern is uncomfortable; the pancreatitis pattern is an emergency.

Can Wegovy actually cause pancreatitis, or is it a coincidence?

The question of whether semaglutide directly causes pancreatitis, or whether people on Wegovy who develop it would have done so anyway, is one researchers continue to examine. What the evidence shows is that GLP-1 receptor agonists as a class have been associated with pancreatitis in post-marketing surveillance, and the risk is reflected in the prescribing information for Wegovy. The MHRA's 2026 update confirmed this is a recognised (not theoretical) risk.

The absolute risk remains low. In the STEP 1 clinical trial, published in the New England Journal of Medicine, pancreatitis events were rare. That doesn't mean the risk is zero, and the regulator's position is clear: any new severe abdominal pain in someone using semaglutide should be investigated promptly, with treatment suspended until pancreatitis has been ruled out.

Some individuals carry a higher baseline risk: a previous episode of pancreatitis, gallstones, heavy alcohol use, or very high triglyceride levels can all raise the likelihood of pancreatic inflammation independent of any medicine. Our detailed look at pancreatitis risk with semaglutide covers the evidence on these compounding factors. This is exactly the kind of history a prescriber needs before agreeing to treatment, not because it automatically rules Wegovy out, but because it changes the clinical calculus.

What a prescriber checks, and what you can do to reduce your risk

A thorough clinical review before starting Wegovy is the first layer of protection. At nume, every consultation is read by a GPhC-registered prescriber, a clinician reviews your answers the same day, not software running an eligibility filter. They look at your medical history, current medicines, and any comorbidities that affect how safely you can use semaglutide.

Beyond that, there are practical steps while on treatment. Keeping well hydrated matters, particularly if GI side effects are causing vomiting or reduced fluid intake, dehydration can strain the pancreas independently. Spreading fat intake across meals rather than eating large fatty portions in one sitting is sensible on any GLP-1 treatment. If you've had gallstones or your triglycerides have been flagged as high, your prescriber should know this at the outset. Our page on avoiding pancreatitis on Wegovy goes into practical prevention in more detail, as does our guide on prevention strategies during treatment.

One thing that helps: if you feel your stomach pain is worse than expected and you're not sure whether to call someone, call anyway. Every GP surgery and NHS 111 line is set up to field exactly that kind of query. The tablet on your phone at half past seven in the morning (before the kettle has finished boiling) is all it takes to get advice from someone who can tell you whether to wait or be seen. Don't try to self-diagnose pancreatitis on the basis of a forum post.

Reporting a side effect and getting further support

If you suspect pancreatitis or any serious reaction to Wegovy, report it to the MHRA through the Yellow Card scheme. You don't need to wait for a confirmed diagnosis, suspected side effects are exactly what Yellow Card is designed to capture, and reporting helps the regulator monitor safety signals across the whole population using these medicines. Patients, carers and healthcare professionals can all submit a report.

For a broader picture of what to expect from treatment, our Wegovy side effects page covers the full range, from the common GI effects to the less frequent ones the prescribing information lists. If you're weighing up whether Wegovy is the right option given your health history, our Wegovy overview sets out how the medicine works, who it's licensed for, and what the clinical trial evidence shows. Further questions about treatment can also be explored through our FAQs.

Our prescribers discuss suitability and side effects as part of every consultation, including pancreatitis risk for those with relevant history. Check your eligibility to start a free consultation today.